473 related articles for article (PubMed ID: 28699667)
21. Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.
Shah BD; Martin P; Sotomayor EM
Cancer Control; 2012 Jul; 19(3):227-35. PubMed ID: 22710898
[TBL] [Abstract][Full Text] [Related]
22. Up-Front ASCT Overcomes the Survival Benefit Provided by HDAC-Based Induction Regimens in Mantle Cell Lymphoma: Data from a Real-Life and Long-Term Cohort.
de Pádua Covas Lage LA; Elias MDV; Reichert CO; Culler HF; de Freitas FA; de Oliveira Costa R; Rocha V; da Siqueira SAC; Pereira J
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835453
[TBL] [Abstract][Full Text] [Related]
23. Mantle cell lymphoma shows three morphological evolutions of classical, intermediate, and aggressive forms, which occur in parallel with increased labeling index of cyclin D1 and Ki-67.
Kimura Y; Sato K; Arakawa F; Karube K; Nomura Y; Shimizu K; Aoki R; Hashikawa K; Yoshida S; Kiyasu J; Takeuchi M; Nino D; Sugita Y; Morito T; Yoshino T; Nakamura S; Kikuchi M; Ohshima K
Cancer Sci; 2010 Mar; 101(3):806-14. PubMed ID: 20002441
[TBL] [Abstract][Full Text] [Related]
24. B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression.
Gambino S; Quaglia FM; Galasso M; Cavallini C; Chignola R; Lovato O; Giacobazzi L; Caligola S; Adamo A; Putta S; Aparo A; Ferrarini I; Ugel S; Giugno R; Donadelli M; Dando I; Krampera M; Visco C; Scupoli MT
Sci Rep; 2024 Mar; 14(1):6595. PubMed ID: 38503806
[TBL] [Abstract][Full Text] [Related]
25. Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma.
Hill HA; Jain P; Ok CY; Sasaki K; Chen H; Wang ML; Chen K
Cancer Res Commun; 2023 Aug; 3(8):1435-1446. PubMed ID: 37538987
[TBL] [Abstract][Full Text] [Related]
26. [Clinical features and prognostic factors of elderly patients with mantle cell lymphoma].
Hao XY; Yang P; Zhang W; Liu H; Sun XH; Xiao XB; Wang JW; Li ZL; Li LH; Wang SY; He J; Li XL; Jing HM
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):495-500. PubMed ID: 37550206
[No Abstract] [Full Text] [Related]
27. Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma.
Lymphoma Research Foundation LRF
Oncology (Williston Park); 2024 Feb; 38(2):51-67. PubMed ID: 38421601
[TBL] [Abstract][Full Text] [Related]
28. Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.
Burkart M; Karmali R
J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330376
[TBL] [Abstract][Full Text] [Related]
29. Bulky primary tibia mantle cell lymphoma achieved complete remission with CHOP and DHAP plus rituximab: A case report.
Chen S; Ye M
Oncol Lett; 2018 Nov; 16(5):6116-6120. PubMed ID: 30344753
[TBL] [Abstract][Full Text] [Related]
30. Frontline therapy and role of high-dose consolidation in mantle cell lymphoma.
Rule S
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):419-424. PubMed ID: 27913510
[TBL] [Abstract][Full Text] [Related]
31. Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma.
Ferrero S; Grimaldi D; Genuardi E; Drandi D; Zaccaria GM; Alessandria B; Ghislieri M; Ferrante M; Evangelista A; Mantoan B; De Luca G; Stefani PM; Benedetti F; Casaroli I; Zanni M; Castellino C; Pavone V; Petrini M; Re F; Hohaus S; Musuraca G; Cascavilla N; Ghiggi C; Liberati AM; Cortelazzo S; Ladetto M
Blood; 2022 Sep; 140(12):1378-1389. PubMed ID: 35737911
[TBL] [Abstract][Full Text] [Related]
32. Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.
Gribbin C; Chen J; Martin P; Ruan J
Leuk Lymphoma; 2024 Jan; 65(1):1-13. PubMed ID: 37800170
[TBL] [Abstract][Full Text] [Related]
33. Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma.
Rezazadeh A; Pruett J; Detzner A; Edwin N; Hamadani M; Shah NN; Fenske TS
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):254-259. PubMed ID: 38195321
[TBL] [Abstract][Full Text] [Related]
34. Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents.
Jain N; Mamgain M; Chowdhury SM; Jindal U; Sharma I; Sehgal L; Epperla N
J Hematol Oncol; 2023 Aug; 16(1):99. PubMed ID: 37626420
[TBL] [Abstract][Full Text] [Related]
35. Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma.
Nikkarinen A; Lokhande L; Amini RM; Jerkeman M; Porwit A; Molin D; Enblad G; Kolstad A; Räty R; Hutchings M; Weibull CE; Hollander P; Ek S; Glimelius I
Blood Adv; 2023 Sep; 7(18):5304-5313. PubMed ID: 37389827
[TBL] [Abstract][Full Text] [Related]
36. Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium.
Vose JM; Fu K; Wang L; Mansoor A; Stewart D; Cheng H; Smith L; Yuan J; Qureishi HN; Link BK; Cessna MH; Barr PM; Kahl BS; Mckinney MS; Khan N; Advani RH; Martin P; Goy AH; Phillips TJ; Mehta A; Kamdar M; Crump M; Pro B; Flowers CR; Jacobson CA; Smith SM; Stephens DM; Bachanova V; Jin Z; Wu S; Hernandez-Ilizaliturri F; Torka P; Anampa-Guzmán A; Kashef F; Li X; Sharma S; Greiner TC; Armitage JO; Lunning M; Weisenburger DD; Bociek RG; Iqbal J; Yu G; Bi C;
J Hematol Oncol; 2023 Dec; 16(1):122. PubMed ID: 38104096
[TBL] [Abstract][Full Text] [Related]
37. Exploring new prognostic biomarkers in Mantle Cell Lymphoma: a comparison of the circSCORE and the MCL35 score.
Salim R; Husby S; Winther Eskelund C; Scott DW; Holte H; Kolstad A; Räty R; Ek S; Jerkeman M; Geisler C; Sommer Kristensen L; Dahl M; Grønbæk K
Leuk Lymphoma; 2023; 64(8):1414-1423. PubMed ID: 37259807
[TBL] [Abstract][Full Text] [Related]
38. Frontline Treatment for Older Patients with Mantle Cell Lymphoma.
Ye H; Desai A; Zeng D; Romaguera J; Wang ML
Oncologist; 2018 Nov; 23(11):1337-1348. PubMed ID: 29895632
[TBL] [Abstract][Full Text] [Related]
39. The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma.
Jiang V; Lee W; Zhang T; Jordan A; Yan F; Cai Q; McIntosh J; Vargas J; Liu Y; Wang M
Biomark Res; 2024 Jun; 12(1):62. PubMed ID: 38886769
[TBL] [Abstract][Full Text] [Related]
40. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.
Hess G; Dreyling M; Oberic L; Gine E; Zinzani PL; Linton K; Vilmar A; Jerkeman M; Chen JMH; Ohler A; Stilgenbauer S; Thieblemont C; Lambert J; Zilioli VR; Sancho JM; Jiménez-Ubieto A; Fischer L; Eyre TA; Keeping S; Park JE; Wu JJ; Siddiqi R; Reitan J; Wade S; Salles G
Br J Haematol; 2023 Aug; 202(4):749-759. PubMed ID: 36257914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
